Methotrexate for inflammatory skin disease in pediatric patients: Consensus treatment guidelines
Authors:
- Elaine C. SiegfriedESElaine C. Siegfried
- Lisa M. ArkinLALisa M. Arkin
- Yvonne E. ChiuYCYvonne E. Chiu
- Adelaide A. HebertAHAdelaide A. Hebert
- Jeffrey P. CallenJCJeffrey P. Callen
- Leslie Castelo‐SoccioLCLeslie Castelo‐Soccio
- Dominic O. CoDCDominic O. Co
- Kelly M. CordoroKCKelly M. Cordoro
- Megan L. CurranMCMegan L. Curran
- Austin M. DalrympleADAustin M. Dalrymple
- Carsten FlohrCFCarsten Flohr
Open Access
- 14 June 2023
- journal article
- research article
- Published by Wiley in Pediatric Dermatology
- Vol. 40 (5) , 789-808
Abstract
Methotrexate (MTX) is a readily accessible drug, first used in 1948 and employed for a wide variety of indications since then. However, despite widespread off‐label use, FDA labeling does not include approved indications for the use of MTX for many inflammatory skin diseases in pediatric patients, including morphea, psoriasis, atopic dermatitis, and alopecia areata, among others. Without published treatment guidelines, some clinicians may be hesitant to use MTX off‐label, or uncomfortable prescribing MTX in this population. To address this unmet need, an expert consensus committee was convened to develop evidence‐ and consensus‐based guidelines for use of MTX to treat pediatric inflammatory skin disease. Clinicians with experience and expertise in clinical research, drug development, and treating inflammatory skin disease in pediatric patients with MTX were recruited. Five committees were created based on major topic areas: (1) indications and contraindications, (2) dosing, (3) interactions with immunizations and medications, (4) adverse effects (potential for and management of), and (5) monitoring needs. Pertinent questions were generated and addressed by the relevant committee. The entire group participated in a modified Delphi process to establish agreement on recommendations for each question. The committee developed 46 evidence‐ and consensus‐based recommendations, each with >70% agreement among members, across all five topics. These are presented in tables and text, along with a discussion of supporting literature, and level of evidence. These evidence‐ and consensus‐based recommendations will support safe and effective use of MTX for the underserved population of pediatric patients who may benefit from this valuable, time‐honored medication.Keywords
Funding Information
- National Eczema Association
- National Psoriasis Foundation
- Pediatric Dermatology Research Alliance
This publication has 112 references indexed in Scilit:
- Interactions among Low Dose of Methotrexate and Drugs Used in the Treatment of Rheumatoid ArthritisAdvances in Pharmacological Sciences, 2013
- Development of consensus treatment plans for juvenile localized scleroderma: A roadmap toward comparative effectiveness studies in juvenile localized sclerodermaArthritis Care & Research, 2012
- Is concomitant use of methotrexate and oral retinoids dangerous? A review of the data regarding this combinationJournal of the American Academy of Dermatology, 2011
- 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic featuresArthritis Care & Research, 2011
- Monitoring Methotrexate Toxicity in Juvenile Idiopathic ArthritisThe Journal of Rheumatology, 2009
- Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanerceptRheumatology, 2008
- Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritisAnnals of the Rheumatic Diseases, 2007
- Folate supplementation during methotrexate therapy for patients with psoriasisJournal of the American Academy of Dermatology, 2005
- Methotrexate treatment of recalcitrant childhood dermatomyositisArthritis & Rheumatism, 1992
- Effect of food on the bioavailability of low‐dose methotrexate in patients with rheumatoid arthritisArthritis & Rheumatism, 1992